Course No 9335
If you have any questions, please contact us:
Tel.: +49 (0)6221 / 84 44 0 E-Mail: firstname.lastname@example.org
1/2 Day Pre-Conference Session Appropriate Quality of Excipients
Richard Bonner / Tony Scott / Edit Szõcs
QP survey on excipients: outcome and interpretation of the data
What level of GMP and supplier qualification is needed (and what is too much)
Challenges and solutions
QP Forum, 25 - 26 November 2015
Keynote: The QP Job - what about Ethics and Culture?
Comply or die?
Responsibility, confidence & dialogue: My triangle of orientation
The Falsified Medicines Directive: Harmonisation needed?
The Written Confirmation and the impact on global pharma
Differences of the transposition of the FMD into national law
Different countries - different approaches
The FMD: a more secure supply chain now?
The Falsified Medicines Directive: What will be important?
New packaging design and Change Control
Batch Record Review and batch release
How to handle returns (are all returns falsified medicines?)
What to do in the case of suspected falsification
Data Integrity: what the QP needs to know
Why is it making everybody nervous?
Data Integrity in the own company
Data Integrity with suppliers and contractors
Dr Bob McDowell
PAT and Real Time Release: really a hot Topic for QPs?
What is the current status? (is anyone doing that at all?)
Things to consider for QPs
The link to process validation and master batch documentation
Dr Line Lundsberg-Nielsen
Cross Contamination Observations: what a QP can learn
Poor practices observed
Examples of deficiencies & recommendations
Recalls related to cross contamination
Why QPs should love Statistics (a final Presentation)
The power of statistical techniques and error theory
Statistical interpretation of data
What is necessary for QPs
Parallel Sessions: Working on Case Studies
1) Update on GMP-relevant topics and what QPs are expected to do
Discussion, questions, answers
Bernd Renger and Rainer Gnibl
2) Annex 16 - Status quo and new tasks
Ulrich Kissel and Christina Meissner
3) QP Scenarios - How serious could they be?
Make decisions based on real-life situations
Sue Mann and Gillian Renouf
4) The Role of the QP at the GMP/GCP interface
Where does the IMP QP responsibility end?
Where and when should the IMP QP be involved in the clinical trial (e.g. Site-to-site transfer, temperature excursions, shelf life extension, complaint handling, joint GMP/GCP inspections etc.)
Managing incidents at the GMP/GCP interface
IMP Working Group
5) The QP/GDP Interface
Where does responsibility end and when does it come back?
QP and RP co-operation
Deviations in the supply chain: reporting and handling
Johanna Linnolahti and Aidan Madden
6) The QP and Contracts
What does a QP need to know?
EU regulations vs. non-EU regulations - what counts?
How to keep the overview
Involvement of the QP
Afshin Hosseiny and Monika Hupfauf
You will be able to attend three of these parallel sessions. Please choose the ones you like to attend when you register for the Forum.
During the 2 days of the Forum, delegates can post their questions. The answers will be given by the expert speakers in a dedicated session and/or published in the members' area of the EQPA web-site.